Details of the Drug Combination

General Information of Drug Combination (ID: DCQTACG)

• Drug Combination Name: Nintedanib + Tivantinib
• Indication: Ewing sarcoma; Status: Investigative [1]
• Component Drugs:
  Nintedanib (DMMQ2OW): Small molecular drug
  Tivantinib (DMNVP8Q): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: TC-71
  Zero Interaction Potency (ZIP) Score: 31.708
  Bliss Independence Score: 34.181
  Loewe Additivity Score: 10.121
  LHighest Single Agent (HSA) Score: 16

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Nintedanib

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[3]
Ovarian neoplasm	N.A.	Approved	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]

Indication(s) of Tivantinib

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 3	[5]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]

Tivantinib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
• [3] Nintedanib FDA Label
• [4] ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).